Integer (US:ITGR)2025-07-24 13:00Financial Performance - Sales increased by 11% compared to Q2 2024, with organic sales also up by 11%[14, 61] - Adjusted operating income rose by 15% compared to Q2 2024[14, 61] - Adjusted EPS reached $1.55, a 19% increase from $1.30 in Q2 2024[14, 61] - Free cash flow is up $9 million, +55% compared to 2Q24[42] Outlook - The company narrowed its sales outlook to $1,850 to $1,876 million, reflecting an 8% to 9% increase compared to 2024[14, 61] - Adjusted operating income outlook increased by $2 million at the midpoint, ranging from $319 to $331 million, a 12% to 16% increase vs 2024[12, 14, 61] - Adjusted EPS outlook increased by $0.05 at the midpoint, ranging from $6.25 to $6.51, an 18% to 23% increase vs 2024[12, 14, 61] - Free cash flow is projected to be between $120 to $140 million, up 20% to 40% vs 2024[14, 61] Business Segments - Cardio & Vascular (C&V) trailing 4 quarter sales increased 17% year-over-year in 2Q25[24] - CRM & Neuromodulation trailing 4 quarter sales increased 5% year-over-year in 2Q25[31]